الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 89 |  |  |
| | | from | 89 | | |
Abstract
This study was purposed to determine whether treatment has an effect on biometric parameters of the eye in patients with type II DM who start therapy, using partial coherence interferometry done by Zeiss IOL master 500.
This study was carried out on 50 eyes of 25 diabetes mellitus type II patients presenting for the determination of biometry readings among uncontrolled DM type II patients through Zeiss IOL master 500 before and after glycemic control.
In this study, the distribution of the studied patients according sex represents 11 (44 %) for male and 14 (56 %) for female, with mean age 48.96 ± 7.96 years-old ranged between 40.0 – 67.0 years-old and median (IQR) 47.0 were recruited in this study.
The mean of blood glucose level for pre-treatment was 331.8 ± 30.77 mg/dL ranged between 300.0 – 400.0 mg/dL with median 320.0 (309.0 – 355.0) mg/dL, while mean of blood glucose level for post-treatment was 167.2 ± 10.49 mg/dL ranged between 142.0 – 179.0 mg/dL with median 171.0 (161.0 – 175.0) mg/dL. The mean difference in blood glucose level between pre-treatment and post-treatment decreased by 164.64 ± 27.70 mg/dL, which was statistically significant t 29.718* (p value < 0.001*). The mean of HbA1C for pre-treatment was 10.10 ± 1.13 % ranged between 8.32 – 11.89 % with median 9.81 (9.28 – 11.09) %, while mean of HbA1C for post-treatment was 7.61 ± 0.66 % ranged between 6.48 – 8.81 % with median 7.64 (7.22 – 8.11) %. The mean difference in HbA1C between pre-treatment and post-treatment decreased by 2.49 ± 0.57 %, which was statistically significant t 21.689* (p value < 0.001*)
The mean axial length for pre-treatment was 23.53 ± 1.32 mm ranged between 21.06 – 27.68 mm with median 23.66 (22.3 – 24.3) mm, while the axial length post-treatment was 23.54 ± 1.33 mm ranged between 20.98 – 27.67 mm with median 23.71 (22.4 – 24.4) mm. The mean differences between pre-treatment and post-treatment of axial length was t 1.623 (P value > 0.111) which was statistically non significant.
The mean K1 for pre-treatment was 43.12 ± 1.64 D ranged between 39.85 – 47.20 D with median 43.19(42.1 – 44.1) D, while the K1 for post-treatment was 43.13 ± 1.63 D ranged between 39.73 – 47.10 D with median 43.24 (42.1 – 44.0) D. The mean differences between pre-treatment and post-treatment of K1 was t 1.599 (P value > 0.116) which was statistically non significant.
The mean K2 for pre-treatment was 44.07 ± 1.50 D ranged between 41.38 – 47.47 D with median 44.04(43.1 – 45.1) D, while the K2 for post-treatment was 44.09 ± 1.49 D ranged between 41.43 – 47.33 D with median 44.06 (43.1 – 45.1) D. The mean differences between pre-treatment and post-treatment of K2 was t 1.333 (P value > 0.189) which was statistically non significant.
The mean of residual post IOL refraction for pre-treatment were represents -0.27 ± 0.11 D ranged between -0.46 – -0.05 D with median -0.28 (-0.36 – -0.17) D, while; post-treatment represents -0.31 ± 0.22 D ranged between -0.57 – 0.19 D with median -0.38 (-0.48 – -0.25) D. The mean difference between pre-treatment and post-treatment of residual post IOL refraction was decreased -0.04 ± 0.19 D, which was statistically non significant t 1.556 (p value > 0.126).
Our results revealed that there were no significant changes detected in pre-treatment and post-treatment diabetic eyes in regards to their biometry including their axial length, keratometric readings and IOL power calculations.
Recommendations include a long term study with a relatively larger sample size and measuring changes in central cornel thickness and lens thickness. It is also advised to exclude macular edema before any axial length measurement as that may mess up results.